

## Quick reference guide

# Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma

### Guidance

- 1 Sunitinib is recommended as a first-line treatment option for people with advanced and/or metastatic renal cell carcinoma who are suitable for immunotherapy and have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- 2 When using ECOG performance status score, clinicians should be mindful of the need to secure equality of access to treatments for people with disabilities. Clinicians should bear in mind that people with disabilities may have difficulties with activities of daily living that are unrelated to the prognosis of renal cell carcinoma. In such cases clinicians should make appropriate judgements of performance status taking these considerations into account.
- 3 People who are currently being treated with sunitinib for advanced and/or metastatic renal cell carcinoma but who do not meet the criteria in 1 should have the option to continue their therapy until they and their clinicians consider it appropriate to stop.

### Implementation tools

NICE has developed tools to help organisations put this guidance into practice (listed below). These are available on our website ([www.nice.org.uk/TA169](http://www.nice.org.uk/TA169)).

- Costing tools:
  - costing report to estimate the national savings and costs associated with implementation
  - costing template to estimate the local costs and savings involved.
- Audit support for monitoring local practice.

### Further information

#### Ordering information

You can download the following documents from [www.nice.org.uk/TA169](http://www.nice.org.uk/TA169)

- A quick reference guide (this document) – the recommendations.
- 'Understanding NICE guidance' – a summary for patients and carers.
- The NICE guidance.
- Details of all the evidence that was looked at and other background information.

For printed copies of the quick reference guide or 'Understanding NICE guidance', phone NICE publications on 0845 003 7783 or email [publications@nice.org.uk](mailto:publications@nice.org.uk) and quote:

- N1839 (quick reference guide)
- N1840 ('Understanding NICE guidance').

## Related NICE guidance

For information about NICE guidance that has been issued or is in development, see [www.nice.org.uk](http://www.nice.org.uk)

### Published

- Percutaneous radiofrequency ablation of renal cancer. NICE interventional procedure guidance 91 (2004). Available from [www.nice.org.uk/IPG91](http://www.nice.org.uk/IPG91)
- Improving outcomes in urological cancers. NICE cancer service guidance (2002). Available from [www.nice.org.uk/CSGUC](http://www.nice.org.uk/CSGUC)

### Under development

- Bevacizumab, sorafenib, sunitinib (second-line) and temsirolimus for the treatment of advanced and/or metastatic renal cell carcinoma. NICE technology appraisal guidance (publication expected June 2009).

## Updating the appraisal

This technology appraisal will be considered for review in February 2011. Information about the progress of a review will be available at [www.nice.org.uk/TA169](http://www.nice.org.uk/TA169)

This guidance represents the view of NICE, which was arrived at after careful consideration of the available evidence. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way which would be inconsistent with compliance with those duties.

© National Institute for Health and Clinical Excellence, 2009. All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.